HeartBeam, Inc.
HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company focused on transforming cardiac care through innovative ambulatory cardiac monitoring solutions. The company develops proprietary, patented technology that captures the heart's electrical activity from three dimensions and synthesizes a 12-lead… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What HeartBeam, Inc. does
In the company’s own words
HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company focused on transforming cardiac care through innovative ambulatory cardiac monitoring solutions. The company develops proprietary, patented technology that captures the heart's electrical activity from three dimensions and synthesizes a 12-lead electrocardiogram from these signals, enabling patients to obtain clinical-grade ECG readings outside of traditional healthcare settings.
The company's flagship product, the HeartBeam System, received FDA clearance in December 2024 for arrhythmia assessment and in December 2025 for 12-lead ECG synthesis software. The system comprises a credit card-sized 3D ECG recording device, a patient mobile application, a physician portal, and cloud-based algorithms. Unlike consumer single-lead or six-lead devices, HeartBeam's cable-free technology captures heart signals in three non-coplanar dimensions and synthesizes them into a familiar 12-lead ECG display using a personalized transformation matrix. The synthesized ECG is reviewed by board-certified cardiologists available 24/7/365.
HeartBeam operates in the rapidly expanding connected medical devices market, which is estimated at $66 billion in 2024 and projected to reach $133 billion by 2029. The cardiac monitoring market specifically is expected to reach approximately $18 billion by 2030. The company targets concierge practices, preventive cardiology groups, and hospital-at-home segments for its initial market introduction in early 2026.
The company's intellectual property portfolio includes 25 issued patents worldwide and 35 pending patent applications across multiple jurisdictions. The patent portfolio covers compact mobile three-lead cardiac monitoring devices, ECG patch devices, methods for atrial fibrillation detection, and AI-based diagnostic algorithms. As of December 31, 2025, HeartBeam had 16 employees, with plans to expand strategically aligned with commercialization efforts. The company is pursuing expansion opportunities including heart attack detection indications, an extended-wear 12-lead ECG patch monitor, and AI-based screening and prediction algorithms leveraging longitudinal patient data.
Company details
- Sector
- Healthcare
- Industry
- Surgical & Medical Instruments
- Headquarters
- SANTA CLARA, CA
- Fiscal year end
- December
- CIK
- 1779372
- SIC
- 3841
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns HeartBeam, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · HeartBeam, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do HeartBeam, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of HeartBeam, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in HeartBeam, Inc.'s last four quarterly filings that the numbers alone won't show?”